Navigation Links
Studies on Smoking Genes and Transcriptional Control of Chronic Fatigue Syndrome Revealed in Molecular Medicine
Date:12/23/2008

Smokers who have an easier time quitting may have the benefit of specific genes that can foster success, according to a new study by a team of federal scientists at the National Institute on Drug Abuse.

Manhasset, NY (Vocus) December 23, 2008 -- Smokers who have an easier time quitting may have the benefit of specific genes that can foster success, according to a new study by a team of federal scientists at the National Institute on Drug Abuse. Tomas Drgon, Dean Hamer, George Uhl and their colleagues conducted genome-wide association studies on volunteers with smoking histories and symptoms of nicotine dependence, who were able to successfully stop smoking in community settings, "outside of the somewhat artificial setting of a clinical trial," the authors wrote. The subjects had a specific SNP, single nucleotide polymorphism, which made it easier to stop smoking and remain abstinent. There were SNPs that were more common among those who had trouble quitting and those who stopped without much trouble. In short, subjects who smoke or have smoked had a different genetic allele frequency than those who never smoked. Other researchers have also found similar patterns in genome-wide association studies with cigarettes and other drugs of abuse - a phenotype of substance dependence.

The authors did not find genetic linkage in social smokers (people who smoked at low and steady levels but who were not dependent on cigarettes).

These findings are "reassuring for future attempts to use genotype-based data to match smokers with the type and/or intensities of treatments that provide the best and most cost-effective smoking cessation opportunities for them in community settings," the authors wrote.

Other studies in the January-February 2009 issue of Molecular Medicine include ''Transcriptional Control of Chronic Fatigue Syndrome'' and ''Human AM/AMBP1 as a Treatment for Sepsis.''

Molecular Medicine is published by The Feinstein Institute for Medical Research, part of the North Shore-LIJ Health System. To read the journal online and view this month's popular podcast go to www.molmed.org. For more information contact Assistant Editor, Veronica Davis at 516-562-2670.

###

Read the full story at http://www.prweb.com/releases/Molecular/Medicine/prweb1789394.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Rockefeller Universitys Center for Clinical and Translational Science funds 18 new pilot studies
2. Genome-wide Association Studies Must Account for Ancestry
3. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
4. Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkins Lymphoma
5. Dismissed leukemia drug helps cll patients, studies show
6. Studies examine quality of care for hospitalized sickle cell disease patients
7. FRC: New Mental Health Studies Dispel Myth That Abortion Is A Non-Event
8. MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
9. Journal CHEST: December highlighted studies
10. Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
11. MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Studies on Smoking Genes and Transcriptional Control of Chronic Fatigue Syndrome Revealed in Molecular Medicine 
(Date:12/7/2016)... San Fernando Valley, CA (PRWEB) , ... December 07, 2016 , ... ... Sculptra can be used in several ways to restore a more youthful appearance to ... doctors , now offer Sculptra, along with a variety of other treatments, to rejuvenate ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, a ... the US market its advanced highly customizable contact technology solutions. , ODU Single ... advanced technologies are ideal for a wide range of applications that require customization ...
(Date:12/7/2016)... ... ... AlignLife clinics nationwide are giving back to their communities by collecting toys during ... wrapped tightly under a Christmas Tree. AlignLife hopes to spread the joy and ... exchange for generous donations, customers will receive a gift in return. Anyone who ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. ... season by donating a portion of proceeds to two local organizations: North Chicago Animal ... Control & Friends is a team of authorized and trained volunteers who support ...
(Date:12/7/2016)... California (PRWEB) , ... December 07, 2016 , ... "ProBrand ... any and all media," said Christina Austin - CEO of Pixel Film Studios. , ... with easy to use drop zones. Editors can select from a variety of flip ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)...  Alopexx Oncology, LLC announced data from a Phase ... (immunocytokine) composed of interleukin-2 and a CD20-targeting monoclonal antibody. ... cells as Rituxan and maintains the activities of both ... in tumor targeting, engagement of the immune system, and ... the study (abstract #95954) were presented at the 58 ...
(Date:12/6/2016)... -- Diabetes & Obesity Drug Development Pipeline Review, 2016 ... is currently dominated by therapeutics indicated for type 1 ... and the majority of the pipeline, in terms of ... these indications. While products indicated for obesity do not ... large number of these products in the pipeline, with ...
(Date:12/6/2016)... The pen needles market is projected to reach USD ... 2016, growing at a CAGR of 11.2% during the ... years, the pen needles market has witnessed various technological ... for safety injections in the healthcare industry. These advancements ... with an aim to reduce pain, increase comfort, and ...
Breaking Medicine Technology: